Journal of Thrombosis and Thrombolysis

Article	Citations
COVID-19 update: Covid-19-associated coagulopathy	477
Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum	317
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2	230
COVID-19-associated vasculitis and vasculopathy	211
COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature	188
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors	180
Neutrophil extracellular traps and thrombosis in COVID-19	176
Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia	153
Heparin resistance in COVID-19 patients in the intensive care unit	129
The association between treatment with heparin and survival in patients with Covid-19	126
Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients	118
Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis	112
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis	81
Anticipating the long-term cardiovascular effects of COVID-19	79
Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19	73
COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness	67
Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report	66
Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients	64
Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis	64
High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there?	62
Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy	60
Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review	58
Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19	58
DVT incidence and risk factors in critically ill patients with COVID-19	58
Anticoagulant treatment in COVID-19: a narrative review	56

Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE	54
Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients	52
Risk factors for intracerebral hemorrhage in patients with COVID-19	48
Covid-19 treatment update: follow the scientific evidence	42
Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19	40
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19	39
COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis	39
COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?	38
Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis	38
Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19	37
Incidence of thrombotic complications in COVID-19	37
In vivo demonstration of microvascular thrombosis in severe COVID-19	36
Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series	36
Pulmonary thrombosis in Covid-19: before, during and after hospital admission	35
Thrombophilia screening revisited: an issue of personalized medicine	34
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis	33
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting	32
Rotational thromboelastometry results are associated with care level in COVID-19	32
Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus	32
Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis	31
Major bleeding complications in critically ill patients with COVID-19 pneumonia	31
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum	30
Ovarian vein thrombosis after coronavirus disease (COVID-19) infection in a pregnant woman: case report	29
The administration of rtPA before mechanical thrombectomy in acute ischemic stroke patients is associated with a significant reduction of the retrieved clot area but it does not influence revasculariz	29
Immature platelets in patients hospitalized with Covid-19	29
Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis	28
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis	28
Impact of the COVID-19 pandemic on hyperacute stroke treatment: experience from a comprehensive stroke centre in Singapore	27
Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19	27
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients	27
SARS-CoV-2 infection and thrombotic complications: a narrative review	26
COVID-19 and its sequelae: a platform for optimal patient care, discovery and training	26
Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines	25
The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells	25
Impact of Coronavirus Disease 2019 outbreak on acute coronary syndrome admissions: four weeks to reverse the trend	25
Thromboelastography findings in critically ill COVID-19 patients	24
Successful use of tPA for thrombolysis in COVID related ARDS: a case series	24
Sudden death due to acute pulmonary embolism in a young woman with COVID-19	24
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy	23
Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products	23
Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic	22
Aortic thrombus in patients with severe COVID-19: review of three cases	22
Value-based assessment of implementing a Pulmonary Embolism Response Team (PERT)	21
External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19	20
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage	20
Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel	20
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19	20
Toward understanding the 2019 Coronavirus and its impact on the heart	20
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation	19
Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19	19

Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease	19
A comprehensive review of vascular complications in COVID-19	19
Serotonin: a platelet hormone modulating cardiovascular disease	19
Increased intracranial hemorrhage of mechanical thrombectomy in acute ischemic stroke patients with atrial fibrillation	19
Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation	19
High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards	18
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines	18
Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?	18
Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review	18
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data	17
CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients	17
Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)	17
Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?	17
Filter clotting with continuous renal replacement therapy in COVID-19	17
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design	17
Thrombosis in VEXAS syndrome	17
Arterial and venous involvement in Behçet’s syndrome: a narrative review	16
Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic	16
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis	16
Lupus anticoagulant and mortality in patients hospitalized for COVID-19	16
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	16
Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review	15
Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy in acute limb ischaemia	15
Significant reductions in apoptosis-related proteins (HSPA6, HSPA8, ITGB3, YWHAH, and PRDX6) are involved in immune thrombocytopenia	15
Hyperacute multi-organ thromboembolic storm in COVID-19: a case report	15
Clinical significance of healed plaque detected by optical coherence tomography: a 2-year follow-up study	15
Acute pulmonary embolism in COVID-19 related hypercoagulability	15
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19	14
Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery	14
ST-segment elevation in patients with COVID-19: a systematic review	14
Roles of factor Xa beyond coagulation	14
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation	14
A case of thrombotic thrombocytopenic purpura associated with COVID-19	14
Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis	14
Association of ABO blood group type with cardiovascular events in COVID-19	14
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019	14
Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate	14
Predictors for layered coronary plaques: an optical coherence tomography study	14
Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease	13
Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19	13
Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis	13
Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis	13
COVID 19 infection associated with thrombotic thrombocytopenic purpura	13
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population	13
Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue nacrosis factor-α induced nuclear factor-κappa B signal	13
Circadian variations in pathogenesis of ST-segment elevation myocardial infarction: an optical coherence tomography study	13
Occurrence of pulmonary embolism related to COVID-19	13
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics	13
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome	13
Platelet microvesicles are associated with the severity of coronary artery disease: comparison between peripheral and coronary circulation	13
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies	13
Prior use of anticoagulation is associated with a better survival in COVID-19	12
Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients	12
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia	12
Mitochondria and chronic effects of cancer therapeutics: The clinical implications	12
Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis	12
One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic	12
PEAR1 polymorphisms as a prognostic factor in hemostasis and cardiovascular diseases	12
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis	12
The clinical characteristic, diagnosis, treatment, and prognosis of cerebral cortical vein thrombosis: a systematic review of 325 cases	12
LncRNA LSINCT5/miR-222 regulates myocardial ischemia‑reperfusion injury through PI3K/AKT pathway	11
Risk factors of postoperative deep vein thrombosis (DVT) under low molecular weight heparin (LMWH) prophylaxis in patients with thoracolumbar fractures caused by high-energy injuries	11
Combining lung ultrasound and Wells score for diagnosing pulmonary embolism in critically ill COVID-19 patients	11
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis	11
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism	11
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis	11
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	11
Reducing state attenuates ectodomain shedding of GPVI while restoring adhesion capacities of stored platelets: evidence addressing the controversy around the effects of redox condition on thrombosis	11
The Impact of platelet–fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease	11
Excessive fibrinolysis detected with thromboelastography in a case of amniotic fluid embolism: fibrinolysis may precede coagulopathy	11
Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: a prospective cohort study	11
Pulmonary Embolism Response Team activation during the COVID-19 pandemic in a New York City Academic Hospital: a retrospective cohort analysis	11
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography	11
Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection	11
Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension	11
COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles	10
Impact of the pandemic of COVID-19 on emergency attendance for stroke and acute myocardial infarction in Beijing, China	10
Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management	10
Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?	10
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis	10

Neurological manifestations of thrombotic microangiopathy syndromes in adult patients	10
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone	10
Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study	10
Treatment of platelet concentrates with the L-carnitine modulates platelets oxidative stress and platelet apoptosis due to mitochondrial reactive oxygen species reduction and reducing cytochrome C rel	10
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study	10
Circ_0003204 knockdown protects endothelial cells against oxidized low-density lipoprotein-induced injuries by targeting the miR-491-5p-ICAM1 pathway	10
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor	10